Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...
Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...
Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...
July 24, 2024 — Scientists have discovered that the serrated edges of Komodo dragons' teeth are tipped with iron. The study gives new insight into how Komodo dragons keep their teeth razor-sharp ...
Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...
If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell ...
Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...
At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ...
Wall Street had its best week of 2024, but nerves are still on edge ahead of the Federal Reserve's upcoming decision on ...
Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Summit Therapeutics (SMMT – Research Report), boosting the price ...
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback